On October 2, 2023 Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that the Japanese Patent Office has granted Compugen a patent for treating cancer with a triple combination of any anti- PVRIG antibody with any anti-TIGIT and anti-PD-1 antibody (Press release, Compugen, OCT 2, 2023, View Source [SID1234635578]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Japanese patent No. JP7348072B2, titled "Triple Combination Antibodies Therapies" augments previously issued patent in Japan by expanding and protecting Compugen’s differentiated and leading triple blockade of the DNAM-1 axis with any anti-PVRIG in combination with any anti-TIGIT and anti-PD-1 antibody.

"We are delighted to strengthen our patent portfolio supporting our leadership in blocking three pathways of the DNAM-1 axis, PVRIG, TIGIT and PD-1", said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen. "Addressing resistance to immunotherapy is a substantial unmet medical need and we are executing on a differentiated clinical strategy to evaluate the benefit of our chemotherapy free, triple immunotherapy combination of COM701, COM902 and pembrolizumab to treat patients with cancer."

Japanese patent No. JP7348072B2 is expected to expire no earlier than June 2038.